Brandon Mancini, MD, MBA, FACRO, discusses the presentations from ASTRO 2026 that may impact the future of prostate cancer, lung cancer, and other diseases.
|Articles|January 1, 2003
Oncology NEWS International
- Oncology NEWS International Vol 12 No 1
- Volume 12
- Issue 1
Smoking Help for the Elderly
WASHINGTON-A seven-state pilot project will study the best way to help older smokers kick their nicotine habit. The program, financed by the Centers for Medicare & Medicaid Services (CMS), will test counseling in person and by phone, a prescription smoking cessation drug, nicotine patches, and education materials.
Advertisement
WASHINGTONA seven-state pilot project will study the best way to help older smokers kick their nicotine habit. The program, financed by the Centers for Medicare & Medicaid Services (CMS), will test counseling in person and by phone, a prescription smoking cessation drug, nicotine patches, and education materials.
The 1-year Medicare Stop Smoking Program will be conducted in Alabama, Florida, Missouri, Nebraska, Ohio, Oklahoma, and Wyoming, which were selected using a formula that included the prevalence of older smokers. Additional information on the program is available at 1-866-652-3446.
Articles in this issue
almost 24 years ago
Phase II Trial of Phenoxodiol in Recurrent Ovarian Cancer Is launchedalmost 24 years ago
FDA Approves New Taxotere Indication as First-Line Therapy for NSCLCalmost 24 years ago
Most Cancer Pain Is Experienced at the Patient’s Homealmost 24 years ago
HHS Unites Its HIV Advisorsalmost 24 years ago
First NCI Health Disparity Grantsalmost 24 years ago
Pain Therapy Improves Quality of Life for Caregiversalmost 24 years ago
Inex to Seek FDA Approval for Onco TCS (Liposomal Vincristine)almost 24 years ago
CD40L-Expressing Dendritic Cells Eliminate Breast Tumors in Micealmost 24 years ago
Safe Handling Tips for Use of Testosterone Gelalmost 24 years ago
Lumpectomy/Mastectomy Equivalent in Early Breast CancerAdvertisement
Related to this article
"We thought there might be a preventive effect towards the development from CHIP to CCUS to MDS, so it’s a sort of a continuum," said Kirsten Grønbæk, MD, PhD.
Ralph V. Boccia, MD, FACP, discussed how time since CAR T-cell therapy and toxicity profiles guide bispecific selection in relapsed multiple myeloma.
Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
Industry payments to oncologists were associated with greater use of the promoted treatment, whether or not it was guideline-preferred for the patient’s cancer.
The phase 2/3 AHEAD-MERIT trial will continue to assess overall survival among patients who received BNT113 plus pembrolizumab for head and neck cancer.
Ralph V. Boccia, MD, FACP, discusses payer models, prior authorization, cost recovery, and patient assistance for bispecifics like teclistamab/daratumumab.
Robot-assisted radical hysterectomy reduced mostly low-grade intraoperative complications vs open surgery in early-stage cervical cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer
2
RYZ101 Improves Progression-Free Survival in Previously Treated GEP-NETs
3
Teclistamab Vs Talquetamab After Relapse on CAR T-Cell Therapy in Multiple Myeloma
4
How Might IMiD Holding Therapy Impact Outcomes in R/R Multiple Myeloma?
5